NCT02205073View on ClinicalTrials.gov

A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Healthy Volunteer

Interventions

DRUG

Placebo RD + AVP SD

Placebo (matching to study drug) repeat doses + intranasal AVP single dose

DRUG

Placebo RD + Placebo SD

Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose

DRUG

RG7314 RD + AVP SD

RG7314 repeat doses + intranasal AVP single dose

Trial Locations (1)

2333

Leiden

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02205073 - A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism | Biotech Hunter | Biotech Hunter